Fibroproliferative diseases are responsible for 45% of deaths worldwide. Fibrosis results from dysregulated tissue repair, triggered by factors like pathogens, allergens, pollution, metabolic dysfunction, and genetic or autoimmune disorders. Despite efforts to understand its pathogenesis, only a few FDA-approved anti-fibrotic drugs exist, primarily for idiopathic pulmonary fibrosis and, since early 2024, Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Inflammation plays a crucial role in fibrogenesis, and the interaction between parenchymal, immune, and collagen-producing cells offers promising avenues for discovering new biomarkers and therapeutic targets. Advances in single-cell transcriptomics, multi-OMICS approaches, CRISPR technology, and insights from clinical trials are deepening our understanding of fibrosis, potentially leading to improved patient outcomes and reduced mortality.
This Research Topic aims to gather cutting-edge articles on the immunological aspects of fibrosis pathogenesis. This interdisciplinary effort will facilitate discussions on the similarities and differences among fibroproliferative diseases, highlighting successes and challenges in enhancing therapeutic interventions, diagnostics, and staging tools. We welcome submissions of basic and translational research, reviews, and mini-reviews on topics including:
- Fibrogenesis in the liver, lung, kidney, heart, gut, and skin
- Novel therapeutic targets and interventions
- Host-pathogen interactions
- The microbiome's role in fibrosis
- Interaction between parenchymal, immune cells, and fibroblasts
- Epithelial-stromal interactions in fibrosis progression
- Discovery and validation of novel urine and blood-based biomarkers
- Combinatorial therapies for fibroproliferative diseases
- Immunometabolism and fibrosis
- Innovative in vitro and in vivo models of fibrosis
- Immune cell diversity and cell-type-specific therapies
- Immunomodulation in fibroproliferative diseases
- Resolution of fibrosis
- The intersection of fibrosis and cancer
Fibroproliferative diseases are responsible for 45% of deaths worldwide. Fibrosis results from dysregulated tissue repair, triggered by factors like pathogens, allergens, pollution, metabolic dysfunction, and genetic or autoimmune disorders. Despite efforts to understand its pathogenesis, only a few FDA-approved anti-fibrotic drugs exist, primarily for idiopathic pulmonary fibrosis and, since early 2024, Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Inflammation plays a crucial role in fibrogenesis, and the interaction between parenchymal, immune, and collagen-producing cells offers promising avenues for discovering new biomarkers and therapeutic targets. Advances in single-cell transcriptomics, multi-OMICS approaches, CRISPR technology, and insights from clinical trials are deepening our understanding of fibrosis, potentially leading to improved patient outcomes and reduced mortality.
This Research Topic aims to gather cutting-edge articles on the immunological aspects of fibrosis pathogenesis. This interdisciplinary effort will facilitate discussions on the similarities and differences among fibroproliferative diseases, highlighting successes and challenges in enhancing therapeutic interventions, diagnostics, and staging tools. We welcome submissions of basic and translational research, reviews, and mini-reviews on topics including:
- Fibrogenesis in the liver, lung, kidney, heart, gut, and skin
- Novel therapeutic targets and interventions
- Host-pathogen interactions
- The microbiome's role in fibrosis
- Interaction between parenchymal, immune cells, and fibroblasts
- Epithelial-stromal interactions in fibrosis progression
- Discovery and validation of novel urine and blood-based biomarkers
- Combinatorial therapies for fibroproliferative diseases
- Immunometabolism and fibrosis
- Innovative in vitro and in vivo models of fibrosis
- Immune cell diversity and cell-type-specific therapies
- Immunomodulation in fibroproliferative diseases
- Resolution of fibrosis
- The intersection of fibrosis and cancer